JAMA Clinical Reviews Pharmaceutical Pricing: JAMA Talks With Mark Cuban
24 snips
Feb 12, 2026 
Mark Cuban, entrepreneur and cofounder of the Cost Plus Drug Company, pushes for price transparency and cost‑based drug pricing. He discusses how PBMs and insurer formularies create market inefficiency. He explores manufacturer direct-to-consumer distribution, employer negotiation strategies, and proposed payment reforms to curb high drug costs.
AI Snips
Chapters
Transcript
Episode notes
Force Divestiture Of Non-Insurance Assets
- Require the largest insurers to divest non-insurance subsidiaries to remove conflicts and market control.
- Divestiture should include PBMs and other non-insurance businesses to restore market efficiency.
Teach Employers To Audit PBM Deals
- Educate self-insured employers about PBM practices and hidden rebate flows so they can renegotiate benefits.
- Show employers how branded-drug rebates effectively make their sickest employees subsidize plans and increase costs.
Employers Changed Plans After Coaching
- Mark Cuban cites corporate examples like 7-Eleven where employers renegotiated benefits after being educated.
- His public pressure also pushed PBMs to claim greater transparency, though he warns that shifts can hide costs elsewhere.